极早产儿出生时接受有创与无创通气后的住院及神经发育结局
这项观察性队列研究纳入单一 IV 级新生儿重症监护病房 2014 年 1 月 1 日至 2021 年 6 月 30 日全部 230 例 22 0/7–23 6/7 周极早产儿,按出生后首次插管尝试时间分为无创呼吸支持组(>10 分钟,88 例)与有创呼吸支持组(≤10 分钟,142 例)。主要终点 BPD(生理学定义)或 36 周校正胎龄(PMA)前死亡在两组间无差异(无创组 83/88 [94.3%] vs 有创组 129/142 [90.9%];校正 OR 2.09,95% CI 0.60–7.25;P = .24)。严重脑室内出血或 36 周 PMA 前死亡在有创呼吸支持组更低(校正 OR 2.20,95% CI 1.07–4.51;P = .03)。作者认为,出生后最初 10 分钟无创呼吸支持可行,但与插管及早期肺表面活性物质相比未降低 BPD 或死亡风险。
要点
- 主要复合终点 BPD 或 36 周 PMA 前死亡:无创组 83/88(94.3%)vs 有创组 129/142(90.9%),校正 OR 2.09(95% CI 0.60–7.25;P = .24),无统计学差异。
- 严重脑室内出血或 36 周 PMA 前死亡:有创呼吸支持组更低(校正 OR 2.20,95% CI 1.07–4.51;P = .03)。
- 研究纳入 230 例 22 0/7–23 6/7 周极早产儿,无创组 88 例(中位胎龄 23.6 周),有创组 142 例(中位胎龄 23.0 周)。
- 作者结论:出生后最初 10 分钟无创呼吸支持可行,但未降低 BPD 或死亡风险。
适用人群与场景
- 单中心 IV 级新生儿重症监护病房 2014 年 1 月 1 日至 2021 年 6 月 30 日连续出生的全部 230 例胎龄 22 0/7–23 6/7 周(极早产儿)婴儿。
- 排除出生时接受姑息或舒适照护的婴儿。
诊断标准与关键阈值
- 分组:出生后首次插管尝试时间 >10 分钟为无创呼吸支持组(88 例),≤10 分钟为有创呼吸支持组(142 例)。
- 主要终点:BPD(生理学定义)或 36 周校正胎龄(PMA)前死亡的复合结局。
研究设计与关键结果
- 研究类型:观察性队列研究;单中心 IV 级新生儿重症监护病房;样本量 230 例连续纳入的极早产儿。
- 人群:无创组 88 例(中位 [IQR] 胎龄 23.6 [23.4–23.7] 周;女性 45 例 [51.1%];黑人 54 例 [62.1%]);有创组 142 例(中位 [IQR] 胎龄 23.0 [22.4–23.3] 周;女性 71 例 [50.0%];黑人 94 例 [66.2%])。
- 主要终点 BPD 或 36 周 PMA 前死亡:无创组 83/88(94.3%)vs 有创组 129/142(90.9%);校正 OR 2.09(95% CI 0.60–7.25;P = .24),两组无统计学差异。
- 严重脑室内出血或 36 周 PMA 前死亡:有创呼吸支持组更低(校正 OR 2.20,95% CI 1.07–4.51;P = .03)。
证据类型、等级与局限
- 证据类型:观察性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,极早产儿出生后最初 10 分钟无创呼吸支持可行,但与插管及早期肺表面活性物质相比,未降低 BPD 或死亡风险。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Infants with gestational age between 22 0/7 and 23 6/7 weeks (referred to as nano-preterm infants) are at very high risk of adverse outcomes. Noninvasive respiratory support at birth improves outcomes in infants born at 24 0/7 to 27 6/7 weeks' gestational age. Evidence is limited on whether similar benefits of non-invasive respiratory support at birth extend to nano-preterm infants.
OBJECTIVE: To evaluate the hypothesis that intubation at 10 minutes or earlier after birth is associated with a higher incidence of bronchopulmonary dysplasia (BPD) or death by 36 weeks' postmenstrual age (PMA) in nano-preterm infants.
DESIGN, SETTING, AND PARTICIPANTS: This observational cohort study included all nano-preterm infants at a level IV neonatal intensive care unit who were delivered from January 1, 2014, to June 30, 2021. Infants receiving palliative or comfort care at birth were excluded.
EXPOSURES: Infants were grouped based on first intubation attempt timing after birth (>10 minutes after birth and ≤10 minutes as noninvasive and invasive respiratory support at birth groups, respectively).
MAIN OUTCOMES AND MEASURES: The primary outcome was the composite outcome of BPD (physiological definition) or death by 36 weeks' PMA.
RESULTS: All 230 consecutively born, eligible nano-preterm infants were included, of whom 88 (median [IQR] gestational age, 23.6 [23.4-23.7] weeks; 45 [51.1%] female; 54 [62.1%] Black) were in the noninvasive respiratory support at birth group and 142 (median [IQR] gestational age, 23.0 [22.4-23.3] weeks; 71 [50.0%] female; 94 [66.2%] Black) were in the invasive respiratory support at birth group. The incidence of BPD or death by 36 weeks' PMA did not differ between the noninvasive and invasive respiratory support groups (83 of 88 [94.3%] in the noninvasive group vs 129 of 142 [90.9%] in the invasive group; adjusted odds ratio, 2.09; 95% CI, 0.60-7.25; P = .24). Severe intraventricular hemorrhage or death by 36 weeks' PMA was lower in the invasive respiratory support at birth group (adjusted odds ratio, 2.20; 95% CI, 1.07-4.51; P = .03).
CONCLUSIONS AND RELEVANCE: This cohort study's findings suggest that noninvasive respiratory support in the first 10 minutes after birth is feasible but is not associated with a decrease in the risk of BPD or death compared with intubation and early surfactant delivery in nano-preterm infants.
参考来源
- Shukla VV, Souder JP, Imbrock G, et al. Hospital and Neurodevelopmental Outcomes in Nano-Preterm Infants Receiving Invasive vs Noninvasive Ventilation at Birth. JAMA Netw Open. 2022. PMID: 36036932. doi:10.1001/jamanetworkopen.2022.29105
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。